- Home
- LYEL vs GBLI Comparison
LYEL vs GBLI Comparison
Compare LYEL & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- GBLI
- Stock Information
- Founded
- LYEL 2018
- GBLI 2016
- Country
- LYEL United States
- GBLI United States
- Employees
- LYEL N/A
- GBLI N/A
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- GBLI Property-Casualty Insurers
- Sector
- LYEL Health Care
- GBLI Finance
- Exchange
- LYEL Nasdaq
- GBLI Nasdaq
- Market Cap
- LYEL 369.4M
- GBLI 393.6M
- IPO Year
- LYEL 2021
- GBLI 2003
- Fundamental
- Price
- LYEL $24.74
- GBLI $27.49
- Analyst Decision
- LYEL Buy
- GBLI
- Analyst Count
- LYEL 3
- GBLI 0
- Target Price
- LYEL $16.67
- GBLI N/A
- AVG Volume (30 Days)
- LYEL 33.9K
- GBLI 9.5K
- Earning Date
- LYEL 11-12-2025
- GBLI 10-30-2025
- Dividend Yield
- LYEL N/A
- GBLI 5.09%
- EPS Growth
- LYEL N/A
- GBLI N/A
- EPS
- LYEL N/A
- GBLI 1.94
- Revenue
- LYEL $41,000.00
- GBLI $441,717,000.00
- Revenue This Year
- LYEL N/A
- GBLI $5.48
- Revenue Next Year
- LYEL N/A
- GBLI $7.91
- P/E Ratio
- LYEL N/A
- GBLI $14.19
- Revenue Growth
- LYEL N/A
- GBLI N/A
- 52 Week Low
- LYEL $7.65
- GBLI $25.88
- 52 Week High
- LYEL $24.80
- GBLI $37.00
- Technical
- Relative Strength Index (RSI)
- LYEL 78.41
- GBLI 48.10
- Support Level
- LYEL $16.95
- GBLI $25.88
- Resistance Level
- LYEL $18.13
- GBLI $29.70
- Average True Range (ATR)
- LYEL 1.59
- GBLI 0.46
- MACD
- LYEL 0.66
- GBLI -0.07
- Stochastic Oscillator
- LYEL 93.86
- GBLI 58.38
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance world-wide. The company's two segments are: Penn-America and Non-Core Operations. The Penn-America segment offers specialty property and casualty products designed for its Wholesale Commercial, Specialty Products, InsurTech, and Assumed Reinsurance product offerings. These product lines are offered in the excess and surplus lines marketplace; and Non-Core Operations segment contains lines of business that have been de-emphasized or are no longer being written. The majority of its revenue is from the the Penn-America segment . Geographically, the majority is from California.